Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment with Omalizumab in food allergic children
2018-004427-37Phase 4Terminated
- Sponsor
- Odense Research Center for Anaphylaxis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, double-blind trial of omalizumab in food allergy, anaphylaxis and seafood allergy (2 arms), sponsored by Odense Research Center for Anaphylaxis. Started Jan 2019; status: terminated.
02
Drugs
omalizumab
03
Conditions
food allergyanaphylaxisseafood allergy
Beyond the preview
Go deeper on 2018-004427-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004427-37.